Impact of Potential Blockers on Ru(III) Complex Binding to Human Serum Albumin
Author Information
Author(s): Lilianna Trynda-Lemiesz, Marek Luczkowski
Primary Institution: Faculty of Chemistry, University of Wroclaw
Hypothesis
The study investigates how aspirin, vitamin B2, and warfarin affect the binding of ruthenium complexes to human serum albumin.
Conclusion
Aspirin, vitamin B2, and warfarin can partially block the binding sites of ruthenium complexes on human serum albumin, potentially affecting drug pharmacology and efficacy.
Supporting Evidence
- Aspirin, vitamin B2, and warfarin bind to the IIA subdomain of human serum albumin.
- Binding of these drugs leads to partial blocking of the ruthenium binding site.
- About 80% of ruthenium complexes bind to human serum albumin.
Takeaway
This study looks at how certain drugs can change how well a cancer treatment sticks to a protein in our blood, which might make the treatment work better or worse.
Methodology
The study used UV/visible, circular dichroism, fluorescence spectroscopy, and inductively coupled plasma-atomic emission spectroscopy to analyze the interactions.
Want to read the original?
Access the complete publication on the publisher's website